Loading market dashboard
NYLI Hedge Multi-Strategy Tracker ETF
QAIFinancial ServicesAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NYLI Hedge Multi-Strategy Tracker ETF (QAI) aims to replicate hedge fund performance but falls short in both construction and returns. QAI's top holdings are heavily weighted toward floating-rate bonds and European equities, diverging from typical hedge fund strategy allocations. QAI's 5-year CAGR of 2.5% and Sharpe ratio of 0.40 underperform both the equal-weight S&P 500 and peer multi-strategy ETFs.
Toronto, Ontario--(Newsfile Corp. - June 1, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announced that members of its senior leadership team will participate in a five-city investor roadshow across Central Europe from June 1 to June 5, 2026. Date City June 1 Munich, Germany June 2 Ljubljana, Slovenia June 3 Budapest, Hungary June 4 Bratislava, Slovakia June 5 Vienna, Austria Advancing Platform Development and Strategic Reach Over recent months, QScreen has continued to expand both its technology platform and strategic advisory network.
Individual voice baseline established on first encounter, deviation measured on every return visit; no additional hardware required; platform now fully integrated across all three signal modalities Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into its multi-signal screening platform, expanding the system from camera and structured clinical intake into a three-modality real-time screening solution. QScreen now assesses physiological, acoustic and behavioral indicators simultaneously during the same intake workflow using existing microphones already present on standard assessment devices.
Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across the same scenarios; 60-day live pilot structured and ready Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening today reports internal validation results for its correctional intake platform across 65 calibrated clinical scenarios tested against published instrument thresholds. By digitizing the high-liability blind spots of correctional intake, QAI transforms a universal institutional risk into a scalable SaaS revenue model with zero-hardware deployment friction.
Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from a camera without requiring blood, breath, or urine testing. Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today announces the appointment of José Humberto "Beto" Vargas García as Strategic Advisor.
Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and simultaneously administers CIWA-Ar, COWS, C-SSRS and 10 further validated clinical instruments in under seven minutes with no hardware and no IT project; former Director of Pentagon Joint Artificial Intelligence Center advancing commercial engagement across US correctional facilities and national defense installations; Canadian correctional health outreach underway Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today provides a commercialization update. The Company has completed development of its QAI physiological AI clinical platform and has commenced outreach to prospective facility partners across correctional health and national defense verticals in Canada and the United States.
NYLI Hedge Multi-Strategy Tracker ETF offers hedge fund strategy replication via ETFs and swaps, with a 0.88% expense ratio. QAI currently emphasizes high-quality debt, notably floating-rate investment grade and short-duration Treasuries. QAI's long-term return, volatility, and drawdown closely match Treasury Inflation-Protected Securities, yet it is more correlated to the S&P 500.
